Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-01-22
2008-01-22
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S365000
Reexamination Certificate
active
07320961
ABSTRACT:
The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
REFERENCES:
patent: 6037157 (2000-03-01), Norbeck et al.
patent: 2004/0192624 (2004-09-01), Kempf et al.
Agarwala et al., “Steady state pharmacokinetic (PK) interaction study of Atazanavir (ATV) with Ritonavir (RTV) in healthy subjects,” Poster presented at the 42ndInterscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, Sep. 27-30th, 2002.
O'Mara et al., “Relationship between uridine diphosphate-glucuronsyl transferase (UDP-GT) 1A1 Genotype and total bilirubin elevations in healthy subjects receiving BMS-232632 and saquinavir,” Poster presented at the 40thInterscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, Sep. 17-20, 2000.
Zucker et al., “Mechanism of indinavir-induced hyperbilirubinemia,” PNAS 98(22):12671-12676 (2001).
Ritter, Joseph K., “Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: Evidence for both genetic and environmental influences”, Hepatology, vol. 30, No. 2, Aug. 1999, pp. 476-484.
Sugatani, Junko, et al., “The Phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear HEPATOLOGY”, vol. 33, No. 5, May 2001-05, pp. 1232-1238.
Baede, P., et al, “Drug interactions with TMC125, a potent next generation NNRTI”, Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, vol. 42, 2002, p. 27 & American Society for Microbiology (ASM) Annual Meeting on Infectious Disease; San Diego, CA, USA; Sep. 27-30, 2002 abstract.
Penzak, Scott, et al., “Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers”, Journal of Clinical Psychopharmacology, vol. 22, No. 4, Aug. 2002, pp. 366-370.
Ouellet Daniele, et al, “Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers”, British Journal of Clinical Pharmacology, vol. 46, No. 2, Aug. 1998, pp. 111-116.
O'Mara E. et al., “Steady state pharmacokinetic interaction study of atazanavir (ATV) with efavirenz (EFV) and ritonavir (RTV) in healthy subjects” Programs and abstracts of the 9thConference on Retroviruses and Opportunistic Infections; Feb. 24-28, 2002, Seattle, Washington. Abstract 444.
A. Radominska-Pandya et al.,Structural and Functional Studies of UDP-Glucoronosyltransferases, Drug Metabolism Reviews 31(4):817-99 (1999).
R.H. Tukey et al.,Human UDP-Glucoronosyltransferases: Metabolism, Expression, and Disease, Ann. Rev. Pharmacol. Toxicol. 40:581-616 (2000).
Bertz Richard J.
Kempf Dale J.
Waring Jeffrey F.
Abbott Laboratories
Henley III Raymond J.
Nenow Lydia
Ward Michael J.
LandOfFree
Method for treating a disease, disorder or adverse effect... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating a disease, disorder or adverse effect..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating a disease, disorder or adverse effect... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2809929